FDA approves Zejula (niraparib) as the only once-daily PARP inhibitor in first-line monotherapy maintenance treatment for women with platinum-responsive advanced ovarian cancer regardless of
Issued: London, UK
- Zejula is the only oral monotherapy available as first-line maintenance treatment for women regardless of?BRCA?mutational status, addressing a high unmet need in ovarian cancer
- New individualised starting dose based on the patient?s baseline weight and/or platelet count approved for first-line maintenance treatment; lower rates of haematological adverse events were observed with the individualised dosing group
- The supplemental New Drug Application was approved under the FDA?s Real-Time Oncology Review pilot program
About Ovarian Cancer
In the US, ovarian cancer impacts nearly 222,000 women annually,[ii]?and it is the fifth most frequent cause of cancer death among women.[iii]?Despite high response rates to platinum-based chemotherapy in the front-line setting, approximately 85% of patients will experience disease recurrence.[iv]?Once the disease recurs, it is rarely curable, with decreasing time intervals to each subsequent recurrence.About Zejula (niraparib)
Niraparib is an oral, once-daily PARP inhibitor that is currently being evaluated in multiple pivotal trials. GSK is building a robust niraparib clinical development programme by assessing activity across multiple tumour types and by evaluating several potential combinations of niraparib with other therapeutics. The ongoing development programme for niraparib includes several combination studies, including a phase III study as a first-line triplet maintenance treatment in ovarian cancer (FIRST).GSK in Oncology
GSK is focused on maximising patient survival through transformational medicines. GSK?s pipeline is focused on immuno-oncology, cell therapy, cancer epigenetics and synthetic lethality. Our goal is to achieve a sustainable flow of new treatments based on a diversified portfolio of investigational medicines utilising modalities such as small molecules, antibodies, antibody drug conjugates and cell therapy, either alone or in combination.Indications and Important Safety Information for ZEJULA
Indications ZEJULA is indicated:- for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy.
- for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.
- for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either:
- a deleterious or suspected deleterious BRCA mutation, or
- genomic instability and who have progressed more than six months after response to the last platinum-based chemotherapy.